NCT05543629 2025-03-18
A Study of BMS-986442 With Nivolumab With or Without Chemotherapy in Solid Tumors and Non-small Cell Lung Cancer
Bristol-Myers Squibb
Phase 1/2 Terminated
Clinical Trials
47 trialsNCT02229084 2024-11-07
Vaccination of High Risk Breast Cancer Patients
University of Arkansas
Phase 1/2 Completed
NCT03693612 2024-08-28
GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors
GlaxoSmithKline
Phase 1/2 Completed
NCT03095612 2024-06-13
Phase 1/2 Trial of Selinexor (KPT-330) With Docetaxel for Non-small Cell Lung Cancer (NSCLC)
University of Texas Southwestern Medical Center
Phase 1/2 Terminated
NCT02735239 2024-03-22
Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Oesophageal Cancer
Ludwig Institute for Cancer Research
Phase 1/2 Completed
NCT02718820 2024-01-09
Pembrolizumab Plus Docetaxel for the Treatment of Recurrent or Metastatic Head and Neck Cancer
Medical University of Vienna
Phase 1/2 Completed
NCT03837353 2023-12-18
A Parallel Arm Phase 1b/2a Study of DKN-01 as Monotherapy or in Combination With Docetaxel for the Treatment of Advanced Prostate Cancer With Elevated DKK1
NYU Langone Health
Phase 1/2 Terminated
NCT02834403 2023-12-15
L-NMMA Plus Taxane Chemotherapy in Refractory Locally Advanced or Metastatic Triple Negative Breast Cancer Patients
The Methodist Hospital Research Institute
Phase 1/2 Completed
NCT02599324 2023-11-18
Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors
Pharmacyclics LLC.
Phase 1/2 Completed
NCT04145700 2023-09-13
CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Synovial Sarcoma
Eli Lilly and Company
Phase 1/2 Terminated
NCT03840915 2023-08-21
M7824 in Combination With Chemotherapy in Stage IV Non-small Cell Lung Cancer (NSCLC)
EMD Serono
Phase 1/2 Completed
NCT03636256 2023-08-14
Evaluation of NanoDoce® in Participants With Urothelial Carcinoma
NanOlogy, LLC
Phase 1/2 Completed
NCT02324543 2023-07-21
Study of Gemcitabine/Taxotere/Xeloda (GTX) in Combination With Cisplatin and Irinotecan in Subjects With Metastatic Pancreatic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1/2 Completed
NCT01824901 2023-06-29
Docetaxel With or Without FGFR Inhibitor AZD4547 in Treating Patients With Recurrent Non-Small Cell Lung Cancer
Eastern Cooperative Oncology Group
Phase 1/2 Completed
NCT01879085 2022-09-21
GemTax
University of Pittsburgh
Phase 1/2 Completed
NCT02494921 2022-08-31
LEE011 (Ribociclib) in Combination With Docetaxel Plus Prednisone in mCRPC
University of California, San Francisco
Phase 1/2 Completed
NCT00193128 2021-11-24
Preoperative Therapy With Oxaliplatin/Docetaxel/Capecitabine and Radiation in Resectable Esophagus Cancer
SCRI Development Innovations, LLC
Phase 1/2 Completed
NCT04165031 2021-11-24
A Study of LY3499446 in Participants With Advanced Solid Tumors With KRAS G12C Mutation
Eli Lilly and Company
Phase 1/2 Terminated
NCT02565901 2021-10-01
Sirolimus, Docetaxel, and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer
University of Washington
Phase 1/2 Terminated
NCT02574078 2021-05-06
CheckMate370
Bristol-Myers Squibb
Phase 1/2 Completed
NCT01217060 2021-04-13
Trimodality Management of T1b Esophageal Cancers
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT01468532 2021-03-25
Docetaxel, Prednisone, and Pasireotide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
Barbara Ann Karmanos Cancer Institute
Phase 1/2 Completed
NCT02401542 2020-03-09
FIERCE-21
Rainier Therapeutics
Phase 1/2 Terminated
NCT01683994 2019-11-08
Cabozantinib Plus Docetaxel and Prednisone for Advanced Prostate Cancer
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
NCT00456989 2019-10-30
Study of Taxotere and Doxil to Treat Advanced Androgen-Independent Prostate Cancer
University of Louisville
Phase 1/2 Completed
NCT01084655 2019-07-30
Study of TAK-700 in Combination With Docetaxel and Prednisone in Men With Metastatic Castration-Resistant Prostate Cancer
Takeda
Phase 1/2 Completed
NCT00669162 2019-07-24
Postoperative Radiation Therapy, Hormonal Therapy and Concurrent Docetaxel for High Risk Pathologic Prostate Cancer
University of Kansas Medical Center
Phase 1/2 Completed
NCT00063934 2019-03-05
Oblimersen Plus Doxorubicin and Docetaxel in Treating Patients With Metastatic or Locally Advanced Breast Cancer
National Cancer Institute (NCI)
Phase 1/2 Terminated
NCT00436501 2019-02-26
VEGF Trap and Docetaxel in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00711243 2019-02-26
Docetaxel, Oxaliplatin, and Fluorouracil in Treating Patients With Metastatic or Unresectable Stomach Cancer, Gastroesophageal Junction Cancer, or Other Solid Tumor
Northwestern University
Phase 1/2 Completed
NCT00390429 2018-12-06
Docetaxel and Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors
University of California, Davis
Phase 1/2 Completed
NCT02379585 2018-04-24
STEFNE
Western Regional Medical Center
Phase 1/2 Terminated
NCT02345772 2018-02-20
Neohttp
Western Regional Medical Center
Phase 1/2 Terminated
NCT02393209 2018-02-07
Docetaxel With or Without TAK-117 (MLN1117) in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer
Takeda
Phase 1/2 Terminated
NCT01418001 2018-01-11
Gemcitabine and Docetaxel in Combination With Pazopanib (Gem/Doce/Pzb) for the Neoadjuvant Treatment of Soft Tissue Sarcoma (STS)
Memorial Sloan Kettering Cancer Center
Phase 1/2 Terminated
NCT00225420 2017-06-01
NRR
UNC Lineberger Comprehensive Cancer Center
Phase 1/2 Completed
NCT00934856 2017-04-06
A Study of Trastuzumab Emtansine (T-DM1) in Combination With Docetaxel, and Potentially Pertuzumab, in Participants With Advanced Breast Cancer
Hoffmann-La Roche
Phase 1/2 Completed
NCT00086957 2017-02-27
Gefitinib, Trastuzumab, and Docetaxel in Treating Patients With Metastatic Breast Cancer
City of Hope Medical Center
Phase 1/2 Completed
NCT00879619 2017-02-01
Taxotere/Prednisone Plus Sunitinib in Chemotherapy-Naïve, Hormone Refractory Prostate Cancer Patients
University of California, Irvine
Phase 1/2 Terminated
NCT00526110 2016-10-31
Docetaxel, 5-Fluorouracil and Oxaliplatin in Adenocarcinoma of the Stomach or Gastroesophageal Junction Patients
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT00861471 2016-06-30
Docetaxel (Taxotere) and Imatinib Mesylate (Gleevec) in Hormone Refractory Prostate Cancer
NYU Langone Health
Phase 1/2 Terminated
NCT00503984 2016-06-09
A Phase I/II Study of Azacitidine, Docetaxel, and Prednisone for Metastatic Prostate Cancer Patients
University of Miami
Phase 1/2 Terminated
NCT00459186 2016-05-16
The Use of RAD001 With Docetaxel in the Treatment of Metastatic, Androgen Independent Prostate Cancer
Dana-Farber Cancer Institute
Phase 1/2 Completed
NCT02127372 2014-09-15
Maximum Tolerated Dose, Safety and Efficacy of Docetaxel / Cisplatin + STI571
Duke University
Phase 1/2 Terminated
NCT00645333 2014-04-04
Phase I/II Study of MK-0752 Followed by Docetaxel in Advanced or Metastatic Breast Cancer
University of Michigan Rogel Cancer Center
Phase 1/2 Completed
NCT00439270 2014-03-28
Study of Dasatinib and Docetaxel in Metastatic Hormone Refractory Prostate Cancer
Bristol-Myers Squibb
Phase 1/2 Completed
NCT00406276 2013-08-23
Phase I/II Trial of RAD001 Plus Docetaxel in Patients With Metastatic or Recurrent Non-Small Cell Lung Cancer
Emory University
Phase 1/2 Terminated